What Is Polygenic Embryo Screening?

DNA functions as the biological blueprint of the human body. Certain diseases arise from a single genetic mutation, these are known as monogenic disorders, such as cystic fibrosis or sickle cell anemia. While impactful, such conditions are relatively rare. In contrast, most common health conditions, including diabetes, cardiovascular disease, depression, and many cancers, are polygenic in nature. They develop through the combined influence of numerous genetic variations, alongside lifestyle and environmental factors.

This is where polygenic embryo screening, also referred to as PGT-P (preimplantation genetic testing for polygenic conditions), becomes relevant. This advanced IVF-based approach analyzes embryos to calculate a polygenic risk score, a statistical assessment of the likelihood that an individual may develop specific complex diseases over their lifetime. Rather than offering certainty, PGT-P provides data-driven risk stratification, enabling more informed decision-making at the earliest stage of human development.

What is IVF DNA Testing?

IVF DNA testing has moved far beyond checking embryos for missing or extra chromosomes or a few single-gene disorders. Modern preimplantation genetic testing now includes polygenic risk scores, which assess hundreds of genetic markers together to estimate the likelihood of developing complex conditions such as diabetes, heart disease, or certain cancers. By analyzing the full genetic profile of embryos created through IVF before implantation, this approach provides a broader, data-driven view of potential health risks. The testing is done while embryos are still in the laboratory, allowing prospective parents to make informed reproductive decisions early in the process, without the ethical and emotional challenges associated with later-stage interventions.

How Does IVF DNA Testing for Disease Risk Actually Work?

The process integrates seamlessly into existing IVF procedures. Here's the step-by-step journey:

• Step 1: Embryo Creation and Development After egg retrieval and fertilization, embryos develop in the laboratory for five to six days until they reach the blastocyst stage, a ball of about 100–200 cells.
  
• Step 2: Biopsy A trained embryologist carefully removes 5-10 cells from the outer layer of the embryo (which will become the placenta, not the baby). This biopsy doesn't harm the embryo's development potential.
• Step 3: Genetic Analysis The DNA from these cells undergoes comprehensive sequencing. Advanced algorithms analyze hundreds to thousands of genetic markers associated with specific diseases. The technology compares the embryo's genetic profile against massive databases containing genetic information from millions of people.
• Step 4: Risk Score Calculation Each embryo receives a polygenic risk score for various conditions. These scores indicate whether an embryo has a lower, average, or higher genetic predisposition compared to the general population.
• Step 5: Informed Decision-Making Armed with this information, you and your fertility team can make more informed decisions about which embryo to transfer first.
  

What Diseases Can Be Detected?

Current IVF DNA testing for disease risk can assess embryos for numerous conditions, including:

Cardiovascular Conditions:

• Coronary artery disease
• Hypertension (high blood pressure)
• Atrial fibrillation
  

Metabolic Disorders:

• Type 1 diabetes
• Type 2 diabetes
• Obesity
  

Mental Health Conditions:

• Schizophrenia
• Bipolar disorder
• Major depression
  

Autoimmune Diseases:

• Rheumatoid arthritis
• Inflammatory bowel disease
  

Cancers:

• Breast cancer
• Prostate cancer
• Colorectal cancer
  

Other Conditions:

• Alzheimer's disease
• Endometriosis
• Asthma
  

Recent research involving 1.5 million individuals has shown that polygenic risk scores can explain up to 23% of the variation in type 2 diabetes risk, and over 75% of the genetic component for conditions like Alzheimer's disease and prostate cancer.

Common Single-gene Disorders That Can be Screened Include:

• Cystic Fibrosis affects the lungs and pancreas, causing thick mucus buildup and breathing difficulties. While modern treatments have extended life expectancy significantly, it remains a serious lifelong condition requiring intensive management.
• Sickle Cell Disease causes red blood cells to become rigid and sickle-shaped, blocking blood vessels and causing pain, organ damage, and premature death. Screening offers affected families the opportunity to have healthy children.
• Huntington's Disease represents a particularly complex ethical situation. This late-onset neurological disorder typically appears in the 30s or 40s, causing progressive movement, cognitive, and psychiatric problems. No cure exists, and the condition is fatal. Some couples use IVF DNA testing for disease risk to avoid passing this mutation to their children, while others face difficult decisions about whether preventing a disease that only emerges in adulthood is appropriate.
• Muscular Dystrophy encompasses several genetic disorders affecting muscle strength and function. Duchenne muscular dystrophy, the most common form, causes progressive weakness and typically leads to wheelchair use by adolescence.
• Thalassemia and other hemoglobinopathies cause severe anemia and require regular blood transfusions and chelation therapy to manage iron overload.
  

The Power of Prevention: Real-World Impact

Studies suggest that couples with five chromosomally normal (euploid) embryos could achieve a 27-67% relative risk reduction for various diseases by selecting embryos with lower polygenic risk scores. To put this in perspective: if your family has a strong history of heart disease, choosing an embryo with a lower genetic risk for coronary artery disease could significantly reduce your child's lifetime risk of developing that condition.

However, and this is crucial, these are risk predictions, not certainties. An embryo with a higher risk score might never develop the disease, while one with a lower score could still be affected. Genetics loads the gun, but lifestyle, environment, and chance pull the trigger.

What About Diseases That Can't Be Cured or Might Recur?

This is where IVF DNA testing for disease risk becomes both powerful and complex. The technology can identify increased risk for conditions across a spectrum:

• Preventable or Manageable Diseases: Many conditions screened for like type 2 diabetes and heart disease, can be significantly influenced by lifestyle choices. Early knowledge allows for proactive prevention through diet, exercise, and medical monitoring.
• Treatable But Chronic Conditions: Diseases like rheumatoid arthritis or inflammatory bowel disease have no cure but can be managed with modern medicine. Knowing the risk allows for earlier intervention and better outcomes.
• Currently Incurable Conditions: Conditions like Alzheimer's disease currently have no cure. However, research into prevention strategies is advancing rapidly. Knowing genetic risk decades in advance could enable participation in preventive clinical trials or adoption of protective lifestyle factors.
• Conditions with Recurrence Risk: For cancers like breast or prostate cancer, even after successful treatment, recurrence remains a concern. Lower genetic risk doesn't eliminate the possibility, but it does shift the odds in your favor.

The key understanding: polygenic risk scores don't determine destiny. They provide information that, combined with medical care and lifestyle choices, can help optimize health outcomes.

The Latest Advancements

The field of IVF DNA testing for disease risk is evolving rapidly:

• Improved Accuracy: New algorithms incorporating data from increasingly diverse populations are making predictions more accurate across different ethnic backgrounds. Early versions of these tests were developed primarily using European ancestry data, but recent validation studies in multi-ancestry populations show significant predictive power across ethnicities.
• Expanded Disease Panels: The number of conditions that can be assessed continues to grow as researchers identify more genetic markers.
• Within-Family Validation: Recent studies examining over 40,000 siblings have confirmed that polygenic risk scores work within families, not just across populations, meaning the technology can genuinely help parents choose between their own embryos.
• Integration with Existing Testing: Polygenic screening is being combined with standard chromosome testing (PGT-A) and single-gene disorder testing (PGT-M) for comprehensive embryo assessment.
  

Important Considerations and Limitations

As a fertility journalist with two decades of experience, I've learned that every advancement comes with caveats. Here's what you need to know:

• It's About Probability, Not Certainty: These tests provide risk estimates, not diagnoses. Many factors beyond genetics influence disease development.
• Not All Diseases Are Equal: Predictive accuracy varies significantly between conditions. Some scores are highly reliable; others are still developing.
• Ethical Complexity: Questions arise about selecting embryos based on disease risk. Where do we draw the line? Most experts agree that screening for serious medical conditions is appropriate, but using the technology for non-medical traits raises concerns.
• Cost Considerations: Polygenic embryo screening typically adds $1,000-$4,000 to IVF costs, and insurance coverage varies.
• Limited Availability: While a few companies offer these services, polygenic embryo screening isn't yet available at most fertility clinics.
• Regulatory Landscape: In the United States, this technology is largely unregulated, making patient education and informed consent crucial.
  

What This Means for Your IVF Journey

If you're considering IVF DNA testing for disease risk, here's how to approach the decision:

1. Educate Yourself: Understand what the test can and cannot tell you. Ask your fertility specialist detailed questions about accuracy, limitations, and implications.
   
2. Consider Your Family History: If your family has a strong history of certain diseases, polygenic screening might provide valuable information.
3. Genetic Counseling: Work with a genetic counselor who can help you interpret results and make informed decisions aligned with your values.
4. Manage Expectations: Remember that even with perfect genetic information, many factors influence health outcomes.
5. Think Long-Term: Consider how this information might affect your child's life, including potential psychological impacts and insurance implications.

Looking Ahead

The integration of IVF DNA testing for disease risk into reproductive medicine represents a paradigm shift in how we think about family planning. For the first time in human history, prospective parents can glimpse their future child's genetic health landscape before pregnancy even begins.

Three-quarters of Americans support using this technology for disease risk assessment, according to recent surveys. Yet nearly all express concerns about potential negative outcomes, a healthy tension that reflects the technology's profound implications.

As this field matures, we'll likely see improved accuracy, expanded disease panels, better integration into clinical practice, and hopefully, clearer regulatory frameworks. The goal isn't to create "perfect" babies, an impossible and ethically troubling concept, but to give families information that helps them make choices aligned with their values while maximizing their future child's health potential.

For couples navigating infertility, IVF DNA testing for disease risk adds another layer of complexity to an already challenging journey. But for many, it also offers something precious: the opportunity to give their long-awaited child the best possible genetic start in life.

Note: The field of polygenic embryo screening is rapidly evolving. According to FertilityIn.com always consult with qualified fertility specialists and genetic counselors to understand how these technologies might apply to your specific situation. The information in this article is for educational purposes and should not replace professional medical advice.